24 May 2018
Immunicum AB: Invitation to Investor Event
Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18:00 CEST. Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session.
Date: Wednesday, June 13, 2018
Time: 18:00 – 20:00 CEST
Location: Kalmar Slott, Kungsgatan 1, 392 33 Kalmar
To register to attend the event, please send an email to firstname.lastname@example.org with your full name.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
Gretchen Schweitzer and Joanne Tudorica
Telephone: +49 172 861 8540
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com